Physician profile
Michael Ukaegbu
NPI 1427254283
$7,001.86
in general payments reported to CMS, 2019-2025
27 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $791 · 2021: $714 · 2022: $491 · 2023: $1,089 · 2024: $1,856 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398 · Education: $31.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.98 |
| Education | $31.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,743.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $731.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $719.83 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $705.94 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.27 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $368.07 | 2023-2025 | |
| Lilly USA, LLC | $328.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $298.41 | 2021-2025 | Recorlev |
| Amgen INC. | $228.95 | 2020-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $202.58 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $197.94 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $152.60 | 2019-2022 | |
| Pfizer INC. | $130.80 | 2019-2025 | |
| Exact Sciences Corporation | $115.72 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $93.72 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $76.89 | 2022-2024 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $71.68 | 2020 | |
| Intuitive Surgical, INC. | $37.20 | 2024 | |
| Janssen Pharmaceuticals, INC | $36.42 | 2020-2021 | |
| Sanofi Pasteur INC. | $36.10 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $27.07 | 2024 | Gemtesa |
| Grifols USA, LLC | $26.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.55 | 2020 | |
| Supernus Pharmaceuticals, INC. | $21.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.83 | 2024 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 | |
| Smith+Nephew, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ukaegbu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.